Literature DB >> 22807984

Overexpression of heparanase multiple antigenic peptide 2 is associated with poor prognosis in gastric cancer: Potential for therapy.

Jun Zhang1, Jianmin Yang, Xiaomei Han, Zhongsheng Zhao, Ling DU, Tong Yu, Huiju Wang.   

Abstract

Tumor-associated antigens (TAAs) trigger a TAA-specific immune response, thus they are the crux of antitumor immunosurveillance. A major advance in tumor immunology in the last 20 years was marked by the verification that CTL or B-cell epitopes rather than integral TAAs induce immunoreactivity. Previous studies on the correlation between heparanase (Hpa) expression and clinical or pathological features have generally used commercial antibodies against full-length Hpa protein rather than the functional epitopes, and the antigen determinants of such antibodies have not yet been defined. In our investigation of Hpa peptide expression in gastric cancer tissues and its association with tumor invasion, metastasis and prognosis, we analyzed Hpa expression in the tissues of 132 patients with gastric cancer using tissue microarray (TMA) technology and immunohistochemical staining. Three self-developed rabbit polyclonal antibodies against Hpa multiple antigenic peptides (MAP) and one commercial polyclonal rabbit antibody against the 50-8 kDa Hpa heterodimer were used. Clinical and pathological significance was evaluated using the Chi-square test and Kaplan-Meier survival curve analysis. The results demonstrated that the positivity rates using the antibody against MAP2 and the commercial antibody were 60.6% (80/132) and 65.2% (86/132), respectively. No expression of either MAP1 or MAP3 was noted in the cancer tissues of the 132 cases. MAP2 behaved in a similar manner to the commercial antibody in that a higher Hpa expression was observed in the cancer tissues with vessel invasion, serosal involvement, distant metastasis, poor differentiation and TNM stages III and IV. Moreover, the patients with a positive Hpa expression had a far poorer prognosis, with lower one-year and five-year survival rates. Our results demonstrate that in a similar manner to full-length Hpa proteins, MAP2 expression is closely associated with the invasion, metastasis and prognosis of gastric cancer. This finding may be of potential use in clinical therapy and in estimating the prognosis of a tumor.

Entities:  

Year:  2012        PMID: 22807984      PMCID: PMC3398369          DOI: 10.3892/ol.2012.703

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  18 in total

Review 1.  Development of heparanase inhibitors for anti-cancer therapy.

Authors:  Hua-Quan Miao; Hu Liu; Elizabeth Navarro; Paul Kussie; Zhenping Zhu
Journal:  Curr Med Chem       Date:  2006       Impact factor: 4.530

2.  Heparanase localization and expression by head and neck cancer: correlation with tumor progression and patient survival.

Authors:  Ilana Doweck; Victoria Kaplan-Cohen; Inna Naroditsky; Edmond Sabo; Neta Ilan; Israel Vlodavsky
Journal:  Neoplasia       Date:  2006-12       Impact factor: 5.715

3.  The close relationship between heparanase and cyclooxygenase-2 expressions in signet-ring cell carcinoma of the stomach.

Authors:  Yasuyuki Ohtawa; Yoshio Naomoto; Yasuhiro Shirakawa; Munenori Takaoka; Toshihiro Murata; Ryotaro Sonoda; Kazufumi Sakurama; Tomoki Yamatsuji; Mehmet Gunduz; Hidetsugu Tsujigiwa; Hitoshi Nagatsuka; Norihiko Terada; Satoshi Itano; Sadayuki Horiki; Kazuyoshi Yanagihara; Motowo Nakajima; Noriaki Tanaka
Journal:  Hum Pathol       Date:  2006-07-07       Impact factor: 3.466

Review 4.  Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis.

Authors:  Uri Barash; Victoria Cohen-Kaplan; Ilana Dowek; Ralph D Sanderson; Neta Ilan; Israel Vlodavsky
Journal:  FEBS J       Date:  2010-08-31       Impact factor: 5.542

Review 5.  Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis.

Authors:  Neta Ilan; Michael Elkin; Israel Vlodavsky
Journal:  Int J Biochem Cell Biol       Date:  2006-07-06       Impact factor: 5.085

Review 6.  Immunotherapy of cancer.

Authors:  Hossein Borghaei; Mitchell R Smith; Kerry S Campbell
Journal:  Eur J Pharmacol       Date:  2009-10-20       Impact factor: 4.432

7.  Hypoxia increases heparanase-dependent tumor cell invasion, which can be inhibited by antiheparanase antibodies.

Authors:  Xiaotong He; Paul E C Brenchley; Gordon C Jayson; Lynne Hampson; John Davies; Ian N Hampson
Journal:  Cancer Res       Date:  2004-06-01       Impact factor: 12.701

Review 8.  Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate.

Authors:  Israel Vlodavsky; Neta Ilan; Annamaria Naggi; Benito Casu
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

9.  Anti-heparanase monoclonal antibody enhances heparanase enzymatic activity and facilitates wound healing.

Authors:  Svetlana Gingis-Velitski; Rivka Ishai-Michaeli; Israel Vlodavsky; Neta Ilan
Journal:  FASEB J       Date:  2007-07-12       Impact factor: 5.191

Review 10.  Interactions between heparan sulfate and proteins: the concept of specificity.

Authors:  Johan Kreuger; Dorothe Spillmann; Jin-ping Li; Ulf Lindahl
Journal:  J Cell Biol       Date:  2006-07-31       Impact factor: 10.539

View more
  5 in total

1.  Inhibition of tumor growth and metastasis by EMMPRIN multiple antigenic peptide (MAP) vaccination is mediated by immune modulation.

Authors:  Elina Simanovich; Vera Brod; Maya M Rahat; Ella Drazdov; Miriam Walter; Jivan Shakya; Michal A Rahat
Journal:  Oncoimmunology       Date:  2016-11-29       Impact factor: 8.110

Review 2.  Heparanase: From basic research to therapeutic applications in cancer and inflammation.

Authors:  Israel Vlodavsky; Preeti Singh; Ilanit Boyango; Lilach Gutter-Kapon; Michael Elkin; Ralph D Sanderson; Neta Ilan
Journal:  Drug Resist Updat       Date:  2016-10-06       Impact factor: 18.500

3.  Glucose-regulated protein 78 and heparanase expression in oral squamous cell carcinoma: correlations and prognostic significance.

Authors:  Fei Xia; Jin Cheng Xu; Pei Zhang; Yuan Yuan Zhang; Qian Wen Zhang; Zhen Hua Chao; Fang Wang
Journal:  World J Surg Oncol       Date:  2014-04-25       Impact factor: 2.754

4.  Development of a biosensor for detection of pleural mesothelioma cancer biomarker using surface imprinting.

Authors:  Aabhas Mathur; Steven Blais; Chandra M V Goparaju; Thomas Neubert; Harvey Pass; Kalle Levon
Journal:  PLoS One       Date:  2013-03-13       Impact factor: 3.240

5.  Helicobacter pylori promotes invasion and metastasis of gastric cancer by enhancing heparanase expression.

Authors:  Li-Ping Liu; Xi-Ping Sheng; Tian-Kui Shuai; Yong-Xun Zhao; Bin Li; Yu-Min Li
Journal:  World J Gastroenterol       Date:  2018-10-28       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.